NCT07129772 - Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma | Biotech Hunter

Enrollment

53

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions

Nasopharyngeal Cancer RecurrentNasopharyngeal Cancinoma (NPC)

Interventions

DRUG

Gemcitabine (GEM)

Gemcitabine, cisplatin and pembrolizumab for up to 6 cycles followed by minimally invasive surgery (either endoscopic nasopharyngectomy or transoral robotic-assisted nasopharyngectomy) and maintenance pembrolizumab for a total of 1 year for locally recurrent nasopharyngeal carcinoma

DRUG

Cisplatin

Gemcitabine, cisplatin and pembrolizumab for up to 6 cycles followed by minimally invasive surgery (either endoscopic nasopharyngectomy or transoral robotic-assisted nasopharyngectomy) and maintenance pembrolizumab for a total of 1 year for locally recurrent nasopharyngeal carcinoma

DRUG

PEMBROLIZUMAB (alone or when added to a regimen above)

Gemcitabine, cisplatin and pembrolizumab for up to 6 cycles followed by minimally invasive surgery (either endoscopic nasopharyngectomy or transoral robotic-assisted nasopharyngectomy) and maintenance pembrolizumab for a total of 1 year for locally recurrent nasopharyngeal carcinoma

Trial Locations (1)

Unknown

Department of Clinical Oncology, Queen Mary Hospital, Hong Kong